877134-77-5 Usage
General Description
1-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)urea is a chemical compound with the molecular formula C17H27BN2O3. It is a urea derivative that contains a boron atom and a phenyl group. 1-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)UREA is commonly used in organic chemistry as a reagent for various synthetic reactions. It has been found to have potential applications in the pharmaceutical industry, specifically in the development of new drugs. Additionally, its boron-containing structure makes it an interesting target for research in the field of organoboron chemistry. As such, 1-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)urea is a versatile and valuable compound with diverse potential uses.
Check Digit Verification of cas no
The CAS Registry Mumber 877134-77-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,7,1,3 and 4 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 877134-77:
(8*8)+(7*7)+(6*7)+(5*1)+(4*3)+(3*4)+(2*7)+(1*7)=205
205 % 10 = 5
So 877134-77-5 is a valid CAS Registry Number.
InChI:InChI=1/C13H19BN2O3/c1-12(2)13(3,4)19-14(18-12)9-5-7-10(8-6-9)16-11(15)17/h5-8H,1-4H3,(H3,15,16,17)
877134-77-5Relevant articles and documents
Rational Design of Potent and Selective Inhibitors of an Epoxide Hydrolase Virulence Factor from Pseudomonas aeruginosa
Kitamura, Seiya,Hvorecny, Kelli L.,Niu, Jun,Hammock, Bruce D.,Madden, Dean R.,Morisseau, Christophe
supporting information, p. 4790 - 4799 (2016/06/13)
The virulence factor cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif) is secreted by Pseudomonas aeruginosa and is the founding member of a distinct class of epoxide hydrolases (EHs) that triggers the catalysis-dependent
NOVEL BIPHENYL COMPOUNDS AND THEIR USE
-
Page/Page column 45, (2010/10/20)
The invention is directed to certain biphenyl compounds. Specifically, the invention is directed to compounds according to Formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and Y are as defined below, and to pharmaceutically-acceptable salts thereo
